Dilshani Induruwage
Research Subjects
Research Interests
Dilshani Induruwage has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Sean J. Barbour
Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada
3 shared publications - Bingyue Zhu
British Columbia Renal Agency, Vancouver, British Columbia, Canada
2 shared publications - Daniel C. Cattran
Division of Nephrology, University of Toronto, Toronto, Ontario, Canada
2 shared publications - Fernando Caravaca-Fontán
Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre , Madrid
2 shared publications - Gema Fernández-Juárez
Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
2 shared publications Manuel Praga
Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain
2 shared publications
Latest Publications
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1119-1131
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
Key Points: Lower eGFR, paraprotein presence, and interstitial fibrosis were associated with a higher risk of kidney outcome. Native disease (versus recurrence post-transplantation), White ethnicity, and lower C4 levels were associated with a lower risk of kidney outcome. A 50% reduction in proteinuria from baseline to a value 2 D: 53%, C-statistic: 0.84 [95% confidence interval, 0.82 to 0.86], integrated calibration index: 0.31) and maintained robustness after internal validation. A 50% reduction in proteinuria from baseline to a value <1 g/d was associated with a lower risk of outcome independent of other risk factors (hazard ratio, 0.35; 95% confidence interval, 0.12 to 0.97). Conclusions: Our study evaluated the baseline clinical and histologic parameters associated with kidney outcomes using the largest C3G/idiopathic IC-MPGN cohort to date. These factors were included in a prediction model to assess individual patient risk. Our results provide an evidence-based definition of proteinuria remission that can be used for patient care and in clinical trials. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_08_27_CJASNAugust.20.8.82.mp3
- 13 June 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (8) , 1119-1131
Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
Key Points: Lower eGFR, paraprotein presence, and interstitial fibrosis were associated with a higher risk of kidney outcome. Native disease (versus recurrence post-transplantation), White ethnicity, and lower C4 levels were associated with a lower risk of kidney outcome. A 50% reduction in proteinuria from baseline to a value 2 D: 53%, C-statistic: 0.84 [95% confidence interval, 0.82 to 0.86], integrated calibration index: 0.31) and maintained robustness after internal validation. A 50% reduction in proteinuria from baseline to a value <1 g/d was associated with a lower risk of outcome independent of other risk factors (hazard ratio, 0.35; 95% confidence interval, 0.12 to 0.97). Conclusions: Our study evaluated the baseline clinical and histologic parameters associated with kidney outcomes using the largest C3G/idiopathic IC-MPGN cohort to date. These factors were included in a prediction model to assess individual patient risk. Our results provide an evidence-based definition of proteinuria remission that can be used for patient care and in clinical trials. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_08_27_CJASNAugust.20.8.82.mp3
- 14 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (6) , 854-865
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Key Points: In phospholipase A2 receptor-membranous nephropathy, clinical variables and antibody levels over 3 or 6 months of treatment were predictors of remission at 1 year. Prediction models at 3 and 6 months had similar performance predicting remission, with the 3-month model allowing for earlier assessment of response. The 3-month and 6-month prediction models could be applied in those treated with supportive therapy, rituximab, calcineurin inhibitors, or cyclophosphamide. Background: In patients with antiphospholipase A2 receptor antibody–associated membranous nephropathy, there is currently no accepted method to predict an individual's probability of remission after treatment with immunosuppression or supportive therapy using changes in antibody levels and clinical variables during the first 3–6 months of therapy. Methods: Using a cohort of 187 patients from the Glomérulopathie extramembraneuse rituximab, Membranous Nephropathy Trial of Rituximab, and Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in primary Membranous Nephropathy clinical trials with antibody levels at baseline ≥14 RU/ml, we derived logistic regression models to predict proteinuria remission at 12 months that can be used at baseline or after 3 or 6 months of treatment. Treatment exposures in the trials included supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Predictors in the models included male sex and baseline and changes in serum albumin, proteinuria, and antibody levels, with or without changes in eGFR. Results: Proteinuria remission at 12 months was achieved in 107 patients. Compared with the model at baseline, the 3-month and 6-month models had better model fit with lower Akaike information criterion (186/158 versus 225) and higher R2 (52.7%/62.4% versus 25.8%), better discrimination with higher C-statistic (0.87 and 0.91 versus 0.75, P < 0.001), and better calibration with lower integrated calibration index (0.89%/2.22% versus 2.51%). The 3-month and 6-month models had no consistent difference in prediction performance, and decision curve analysis demonstrated similar net benefit for treatment decisions based on either model up to a threshold probability of 31%. Prediction performance was similar after internal validation using optimism correction. Prediction performance was maintained within subgroups of different treatment regimens, including supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Conclusions: Either the 3-month or 6-month models can be used in patients with antiphospholipase A2 receptor antibody associated membranous nephropathy after 3 or 6 months of treatment with a variety of immunosuppression or supportive therapy to predict remission status at 12 months.
- 14 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (6) , 854-865
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Key Points: In phospholipase A2 receptor-membranous nephropathy, clinical variables and antibody levels over 3 or 6 months of treatment were predictors of remission at 1 year. Prediction models at 3 and 6 months had similar performance predicting remission, with the 3-month model allowing for earlier assessment of response. The 3-month and 6-month prediction models could be applied in those treated with supportive therapy, rituximab, calcineurin inhibitors, or cyclophosphamide. Background: In patients with antiphospholipase A2 receptor antibody–associated membranous nephropathy, there is currently no accepted method to predict an individual's probability of remission after treatment with immunosuppression or supportive therapy using changes in antibody levels and clinical variables during the first 3–6 months of therapy. Methods: Using a cohort of 187 patients from the Glomérulopathie extramembraneuse rituximab, Membranous Nephropathy Trial of Rituximab, and Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in primary Membranous Nephropathy clinical trials with antibody levels at baseline ≥14 RU/ml, we derived logistic regression models to predict proteinuria remission at 12 months that can be used at baseline or after 3 or 6 months of treatment. Treatment exposures in the trials included supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Predictors in the models included male sex and baseline and changes in serum albumin, proteinuria, and antibody levels, with or without changes in eGFR. Results: Proteinuria remission at 12 months was achieved in 107 patients. Compared with the model at baseline, the 3-month and 6-month models had better model fit with lower Akaike information criterion (186/158 versus 225) and higher R2 (52.7%/62.4% versus 25.8%), better discrimination with higher C-statistic (0.87 and 0.91 versus 0.75, P < 0.001), and better calibration with lower integrated calibration index (0.89%/2.22% versus 2.51%). The 3-month and 6-month models had no consistent difference in prediction performance, and decision curve analysis demonstrated similar net benefit for treatment decisions based on either model up to a threshold probability of 31%. Prediction performance was similar after internal validation using optimism correction. Prediction performance was maintained within subgroups of different treatment regimens, including supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Conclusions: Either the 3-month or 6-month models can be used in patients with antiphospholipase A2 receptor antibody associated membranous nephropathy after 3 or 6 months of treatment with a variety of immunosuppression or supportive therapy to predict remission status at 12 months.
- Top Cited Papers
- 20 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (10) , 1283-1293
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Background: The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clinical variables are currently unknown. Methods: We used a cohort of 85 patients from the Membranous Nephropathy Trial Of Rituximab (MENTOR) with anti-PLA2R antibodies ≥14 RU/ml to identify risk factors for not experiencing proteinuria remission after 12 months of treatment with cyclosporine or rituximab. Three landmark times were considered: at baseline and after 3 and 6 months of treatment. Logistic regression model performance was evaluated using C-statistics and model fit (Akaike information criterion [AIC], R2). Results: The model at baseline that best predicted no remission included anti-PLA2R antibodies >323 RU/ml and creatinine clearance; the best model after 3 months included the change from baseline in both antibody and albumin levels; and the best model after 6 months included antibody levels >14 RU/ml, creatinine clearance, and the change from baseline in albumin. Compared with the model at baseline, the model at 3 months had better model fit (AIC 70.9 versus 96.4, R2 51.8% versus 30.1%) and higher C-statistic (0.93 versus 0.83, P = 0.008). The model at 6 months had no difference in performance compared with the model at 3 months (AIC 68.6, R2 53.0%, C-statistic 0.94, P = 0.67). Conclusions: In patients with membranous nephropathy treated with cyclosporine or rituximab in the MENTOR trial, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_10_09_CJN0000000000000237.mp3
- 20 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (10) , 1283-1293
Top Cited PapersAnti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Background: The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clinical variables are currently unknown. Methods: We used a cohort of 85 patients from the Membranous Nephropathy Trial Of Rituximab (MENTOR) with anti-PLA2R antibodies ≥14 RU/ml to identify risk factors for not experiencing proteinuria remission after 12 months of treatment with cyclosporine or rituximab. Three landmark times were considered: at baseline and after 3 and 6 months of treatment. Logistic regression model performance was evaluated using C-statistics and model fit (Akaike information criterion [AIC], R2). Results: The model at baseline that best predicted no remission included anti-PLA2R antibodies >323 RU/ml and creatinine clearance; the best model after 3 months included the change from baseline in both antibody and albumin levels; and the best model after 6 months included antibody levels >14 RU/ml, creatinine clearance, and the change from baseline in albumin. Compared with the model at baseline, the model at 3 months had better model fit (AIC 70.9 versus 96.4, R2 51.8% versus 30.1%) and higher C-statistic (0.93 versus 0.83, P = 0.008). The model at 6 months had no difference in performance compared with the model at 3 months (AIC 68.6, R2 53.0%, C-statistic 0.94, P = 0.67). Conclusions: In patients with membranous nephropathy treated with cyclosporine or rituximab in the MENTOR trial, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_10_09_CJN0000000000000237.mp3